Humana (HUM) cash flow statement

Managed Health Care · NYSE · Health Care

$443.34 -3.88% Close Nov 17, 2026 Live

TrendArc score 51 of 100 · Health 5.7 · Momentum 8.4 · Moat 5.0 · scored Nov 17, 2026 · How the score works

Free cash flow, fiscal year to December 31, 2025

$398 million

down 83.4% from the year before

Humana generated $398 million of free cash flow in the fiscal year to December 2025: $921 million of cash from operations less $523 million of capital spending. That was 0.3% of revenue, against 2.0% the year before. Over the last four quarters, to September 30, 2026, it was $3.2 billion.

What stands out

  • Dividends paid ($430 million) exceeded free cash flow ($398 million) in the fiscal year to December 2025.

Each sentence is written by a fixed rule from the figures on this page.

Free cash flow and net income, the last 10 fiscal years

$2.00B$4.00B$6.00B2016201720182019202020212022202320242025$1.41BFree cash flow $398MNet income $1.19B$2.00B$4.00B$6.00B20172019202120232025Free cash flow $398MNet income $1.19B

Fiscal years, each labelled by the calendar year it ended in. Every figure is in the statement below.

Where the cash wentFiscal year to December 31, 2025

  1. Cash from operations 0.92
  2. Capital spending -0.52
  3. Free cash flow 0.40
  4. Businesses bought and sold, net 0.03
  5. Investments bought and sold, net 2.76
  6. Net share repurchases -0.15
  7. Dividends -0.43
  8. Debt and other -0.63
  9. Net change in cash 1.98

In billions of US dollars. Outflows are grey, not red: a buyback is not a loss. "Debt and other" closes the gap to the reported change in cash. Buying marketable securities moves cash into short-term investments; the balance sheet shows both.

Cash flow statement, the last 10 fiscal years

In billions of US dollars. Each column is a fiscal year, named by the month it ended; the first column adds up the last four quarters. Cash paid out is a negative number.
Fiscal year toLast 4 quarters
to Sep 2026
Dec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
Operating activities
Net income1.191.212.492.812.933.372.711.682.450.61
Depreciation and amortisation0.820.970.920.840.710.620.570.530.480.47
Stock-based pay0.230.240.210.170.220.180.180.160.140.160.12
Working capital and other items-1.330.580.400.72-1.561.481.84-0.180.960.74
Cash from operations3.730.922.973.984.592.265.645.282.174.051.94
Investing activities
Capital spending-0.57-0.52-0.57-0.79-1.12-1.32-0.96-0.74-0.61-0.52-0.53
Businesses bought and sold, net0.03-0.09-0.232.36-4.19-0.710.00-2.25-0.03-0.01
Investments bought and sold, net2.76-2.25-2.46-2.25-1.05-1.39-0.54-0.22-2.39-0.83
Cash from investing2.27-2.95-3.49-1.01-6.56-3.06-1.28-3.09-2.94-1.36
Financing activities
Debt issued or repaid, net0.300.380.47-1.433.731.08-0.371.170.76-0.09
Shares issued less bought back-0.15-0.15-0.82-1.57-2.10-0.08-1.82-1.01-1.04-3.30-0.09
Dividends paid-0.43-0.43-0.43-0.43-0.39-0.35-0.32-0.29-0.27-0.22-0.18
Other financing-0.94-1.620.682.00-0.28-0.89-0.62-0.641.821.09
Cash from financing-1.22-2.49-0.86-1.913.02-1.96-2.29-0.79-0.940.73
Net change in cash1.98-2.47-0.371.67-1.280.621.71-1.700.171.31
Free cash flow
Free cash flow3.160.402.403.193.470.954.674.551.563.531.41
Free cash flow margin2.1%0.3%2.0%3.0%3.7%1.1%6.1%7.0%2.7%6.6%2.6%

Shares issued less bought back is the cash from shares sold less the cash paid for shares bought back (negative when more was bought back), and includes tax withheld when employees' shares vest. Working capital and other items is cash from operations less net income, depreciation and amortisation, and stock-based pay (calculated by TrendArc). Company filings as standardised by Tiingo; calculations by TrendArc. Rebuilt nightly.

Humana against its peers

CompanyFiscal year toFree cash flowFree cash flow margin
Veeva SystemsVEEV Jan 2026$1.39B43.4%
Quest DiagnosticsDGX Dec 2025$1.36B12.3%
HCA HealthcareHCA Dec 2025$7.69B10.2%
LabcorpLH Dec 2025$1.21B8.6%
CignaCI Dec 2025$8.39B3.1%
CenteneCNC Dec 2025$4.32B2.2%
Cardinal HealthCAH Jun 2026$4.56B1.8%
Elevance HealthELV Dec 2025$3.17B1.6%
HumanaHUM Dec 2025$398M0.3%
Peer median5.8%

Each company's newest fiscal year; some end in other months. The peers are the stock card's peer group.

Next

Follow Humana with a free account.

A watchlist, price alerts and saved chart layouts. No card needed.

Sign up free

No forecast, no recommendation. This page describes Humana from published data; it is not advice to buy, sell or hold any security.

Figures as of the close on Nov 17, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.

The TrendArc score, from 0 to 100, combines three pillars measured from published data, Health (business quality over the last twelve months), Momentum (the price against its moving averages, its 52-week high and the market) and Moat (durability over five years), with the share price's long-run trend. It describes the company as it stands today. It is not a forecast or a recommendation.